• On the clinical study report: the full name of the sponsor and coordinating investigator signatories
of the clinical study report and the identities of the principal investigator(s) who conducted the
trial, which are also subject to publication as explained in the revised CTIS transparency rules.
Note: the relevant signatures should, instead, be anonymised.
All contact details (i.e. e-mail addresses and telephone numbers) of the above-mentioned individuals
should be their professional contact details or functional contact details. If applicable (i.e. in the case of
the principal investigator) those details are also published through the relevant structured data fields.
These contact details should, therefore, not be redacted, or otherwise anonymised, in the documents
uploaded in CTIS. Private contact details should not be provided in structured data fields in CTIS and if
included in the documents, they should be redacted in the published documents. Note that the
scientific and public sponsor contact details are also expected to be functional and not containing
personal data (for example: clinicaltrials@companyX.com).
3.3.2. Anonymisation of personal data of trial participants in the document version ‘for
publication’
Personal data of trial participants may only appear, as applicable, in CTIS documents that are not
subject to publication and encompass personal data in a pseudonymised format (e.g., clinical trial
subject ID number) as well as indirect identifiers such as weight, height, age, gender, etc. These
personal data are to be anonymised in any document version ‘for publication’ (see table III of Annex
I).
Protection of personal data of trial participants in the document version ‘for publication’ should be
achieved by using the entire range of available anonymization techniques that might require
modification of the text, as redaction might not be the most suitable anonymisation technique to retain
a meaningful level of data utility in all cases. The following elements should be considered when
applying anonymisation in the documents to be published:
• The choice of anonymisation techniques
36
In the context of CTIS, no specific anonymisation methodology to protect personal data of clinical trial
participants is prescribed, acknowledging that each anonymisation technique has its own strengths and
weaknesses. The robustness of each anonymisation technique is based upon the anonymisation criteria
and will help in identifying the most suitable technique (or combination of different techniques) to
establish an adequate anonymisation process for a given document or set of documents.
• Data utility
Personal data of trial participants could be present in documents that are not subject to publication
(e.g., notification of serious breaches, unexpected events or urgent safety measures, clinical study
reports ‘not for publication’ version). It should be noted that it is equally important to preserve data
utility in the public version of the documents, as much as possible, whilst ensuring adequate
anonymisation. Besides, a quantitative approach to the measurement of the risk of re-identification
could be favoured. This is particularly important in documents such as the final summary of results.
• The sensitivity of the data
The specificities of the relevant data should be taken into consideration when selecting the most
appropriate anonymisation technique(s). For example, clinical trials conducted on rare diseases and/or
on small populations may carry a high risk of re-identification of trial participants. A thorough risk
assessment should be performed for such scenarios and the anonymisation of personal data should be
adapted to the identified risk. Moreover, such an approach is also applicable to genetic information and
low frequency events (e.g., rare events, extreme values, unusual treatments, pregnancy outcomes).